|
Status |
Public on Sep 21, 2010 |
Title |
SUDHL4_2 |
Sample type |
RNA |
|
|
Channel 1 |
Source name |
SUDHL4 Replicate #2
|
Organism |
Homo sapiens |
Characteristics |
cell type: DLBCL cell line treatment group: Treated with control peptide
|
Extracted molecule |
total RNA |
Extraction protocol |
Rneasy Plus Mini kit (Qiagen)
|
Label |
Cy3
|
Label protocol |
Random priming with 9-mers pre-labeled with either Cy3 or Cy5 according to manufacturer's instructions using the NimbleGen Dual-Color DNA Labeling Kit (cat # 05223547001)
|
|
|
Channel 2 |
Source name |
SUDHL4 Replicate #2
|
Organism |
Homo sapiens |
Characteristics |
cell type: DLBCL cell line treatment group: Treated with Bcl6 inhibitor peptide
|
Extracted molecule |
total RNA |
Extraction protocol |
Rneasy Plus Mini kit (Qiagen)
|
Label |
Cy5
|
Label protocol |
Random priming with 9-mers pre-labeled with either Cy3 or Cy5 according to manufacturer's instructions using the NimbleGen Dual-Color DNA Labeling Kit (cat # 05223547001)
|
|
|
|
Hybridization protocol |
See Roche NimbleGen website and Selzer RR, Richmond TA, Pofahl NJ, Green RD, Eis PS, et al. (2005) Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer 44: 305-319. for details
|
Scan protocol |
Scanning was performed using a GenePix 4000B scanner (Axon Instruments) as previously described in Selzer RR, Richmond TA, Pofahl NJ, Green RD, Eis PS, et al. (2005) Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer 44: 305-319.
|
Data processing |
Raw data files (pair files) were processed with Roche NimbleGen's version of the RMA algorithm (without background correction) in NimbleScan 2.3 software. Probe sets that showed at least a 1.8 log-ratio expression change from CP-treated samples after the administration of RI-BPI (BPI-treated samples) were used to generate a BPI gene expression (GE) signature. We subtracted the BPI-GE signature of BPI-responsive cells (OCI-Ly7, OCI-Ly10, Farage, SUDHL6 and SU-DHL4) from the BPI-GE signature of BPI-resistant cells (Pfeiffer, Toledo, OCI-Ly4 and Karpas422).
|
|
|
Submission date |
Sep 20, 2010 |
Last update date |
Sep 20, 2010 |
Contact name |
Maria Eugenia Figueroa |
E-mail(s) |
mef162@miami.edu
|
Organization name |
University of Miiami
|
Department |
Human Genetics
|
Lab |
Maria Figueroa
|
Street address |
1501 NW 10th Ave, BRB 709A, Locator code C227
|
City |
Miami |
State/province |
FL |
ZIP/Postal code |
33136 |
Country |
USA |
|
|
Platform ID |
GPL6602 |
Series (1) |
GSE24236 |
BCL6 repression of EP300 provides a basis for rational combinatorial therapy in diffuse large B cell lymphomas. |
|